Preclinical safety evaluation of Vernolac, a commercially available polyherbal nutraceutical comprising Vernonia zeylanica, Nigella sativa, Hemidesmus indicus, Smilax glabra, and Leucas zeylanica, in Wistar rats

Vernolac is a commercially available polyherbal formulation comprising Vernonia zeylanica aerial parts, Nigella sativa seeds, Hemidesmus indicus roots, Smilax glabra rhizome, and Leucas zeylanica aerial parts. Although previous in vitro studies have demonstrated the anticancer potential of Vernolac and its active ingredients, safety data are available only for some of the plant ingredients of Vernolac. In the present study, acute and 28-day repeat-dose toxicity of Vernolac were evaluated in Wistar rats in accordance with OECD guidelines 420 and 407, respectively. Acute toxicity was investigated for 14 days after administering a single oral dose of 2000 mg/kg to 10 animals (5 males, 5 females). A repeat-dose toxicity study was conducted, in which the human equivalent therapeutic dose in rats (HED; 165 mg/kg/day), a mid-dose (2 × HED; 330 mg/kg/day), and a high dose (4 × HED; 660 mg/kg/day) were administered to three separate groups, each comprising 10 naive animals (5 males and 5 females), for a period of 28 days. In both acute and repeat-dose studies, no morbidity, mortality, changes in food and water intake, relative organ weights, microscopic changes in organs, hematological changes, or clinical signs of toxicity were observed. In the acute study, a significant increase in AST and ALT levels was observed in males. In the 28-day repeated dose study, a significant reduction in ALT was observed only in females receiving 4x HED. In summary, the LD50 of Vernolac is above 2000 mg/kg, and a dose up to two times the therapeutic daily dose is non-toxic in Wistar rats over 28 days. The liver may be a target organ of toxicity when overdosed.

Authors

Institutions

Publication Details

Journal
PLoS ONE
Published
2026-11-18
DOI
https://doi.org/10.1371/journal.pone.0363076
Primary Topic
Phytochemistry Medicinal Plant Applications
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Preclinical safety evaluation of Vernolac, a commercially available polyherbal nutraceutical comprising Vernonia zeylanica, Nigella sativa, Hemidesmus indicus, Smilax glabra, and Leucas zeylanica, in Wistar rats

Kanishka Sithira Senathilake, Sameera R. Samarakoon, Prasanna Galhena, Gayani Ranaweera et al.
PLoS ONE
Phytochemistry Medicinal Plant Applications
article

Preclinical safety evaluation of Vernolac, a commercially available polyherbal nutraceutical comprising Vernonia zeylanica, Nigella sativa, Hemidesmus indicus, Smilax glabra, and Leucas zeylanica, in Wistar rats

Kanishka Sithira Senathilake, Sameera R. Samarakoon, Prasanna Galhena, Gayani Ranaweera, Shalini K. Wijerathne, Sandani De Vass Gunawardane, Ashein Kothalawala, Arumugam Murugananthan, Tharindu Lakmal Dissanayake, Epitawala Arachchige Oshadi
article en

Abstract

Vernolac is a commercially available polyherbal formulation comprising Vernonia zeylanica aerial parts, Nigella sativa seeds, Hemidesmus indicus roots, Smilax glabra rhizome, and Leucas zeylanica aerial parts. Although previous in vitro studies have demonstrated the anticancer potential of Vernolac and its active ingredients, safety data are available only for some of the plant ingredients of Vernolac. In the present study, acute and 28-day repeat-dose toxicity of Vernolac were evaluated in Wistar rats in accordance with OECD guidelines 420 and 407, respectively. Acute toxicity was investigated for 14 days after administering a single oral dose of 2000 mg/kg to 10 animals (5 males, 5 females). A repeat-dose toxicity study was conducted, in which the human equivalent therapeutic dose in rats (HED; 165 mg/kg/day), a mid-dose (2 × HED; 330 mg/kg/day), and a high dose (4 × HED; 660 mg/kg/day) were administered to three separate groups, each comprising 10 naive animals (5 males and 5 females), for a period of 28 days. In both acute and repeat-dose studies, no morbidity, mortality, changes in food and water intake, relative organ weights, microscopic changes in organs, hematological changes, or clinical signs of toxicity were observed. In the acute study, a significant increase in AST and ALT levels was observed in males. In the 28-day repeated dose study, a significant reduction in ALT was observed only in females receiving 4x HED. In summary, the LD50 of Vernolac is above 2000 mg/kg, and a dose up to two times the therapeutic daily dose is non-toxic in Wistar rats over 28 days. The liver may be a target organ of toxicity when overdosed.

PLoS ONEVol. 21(11)
University of Jaffna (LK), University of Colombo (LK)
Good health and well-being
Phytochemistry Medicinal Plant Applications
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon